The technique of Matrix Induced Autologous
The Royal National Orthopaedic Hospital has completed an extensive trial of ACI versus MACI in the treatment of symptomatic osteochondral defects of the knee. A new technique has now been proposed which is quicker and easier to perform. This is the Gel-Type Autologous
Autologous chondrocyte transplantation has become a possible solution for the treatment of chondral knee lesions. In the last years matrix autologous chondrocyte transplantation procedures were developed by various scientists. We selected a biodegradable, hyaluronian-based biocompatible scaffold for cell proliferation. This nonwoven three-dimensional structure consists of a network of 20 – B5-thick fibers with interstices of variable sizes which constitute an optimal physical support to allow cell-cell contacts, cluster formation, and extracellular matrix deposition in order to create a bioengenerized cartilage Hyalograft C. The easy handling of Hyalograft C in open surgery has suggested us to investigate its possible use by an arthroscopic procedure. Arthroscopic technique has been used from December 2000 in 88 cases. At December 2003 45 patients achieved at least 1 year follow up and 22 patients – 2 years follow up. All the patients were clinically evaluated was analyzed according to the International Repair Cartilage Society score at 12 and 24 months. Returning back to sport was also recorded. We were able to obtain CT scans or MRI images for all patients at 6, 12 and 24 months of follow up. No complications related to the implant and no serious adverse events were observed during the treatment and follow up period. The IKDC objective score improved after 12 months in all patients, showing a normal or nearly normal knee in 96,7% of patients. The mean IKDC subjective score obtained was 41,3 at baseline, 76.9 at the 12 months follow-up control, and 75,9 after 24 months. The worsening of IKDC score was noted in 1 of 22 patients analyzed at 12 and 24 months follow up. A second look arthroscopy was performed in 11 patients at 12 months follow up and a complete healing of the defect and the excellent quality of regenerated cartilage was noted at macroscopic examination. The histological evaluation in 6 cases has demonstrated the hyaline type of new cartilage, although not completely mature. This matrix autologous chondrocyte transplantation procedure avoids the use of periosteal flap, simplify the surgical procedure and permit to perform the arthroscopic implant. Thus, complications as hypertrophy or ossification of periosteal flap are avoided and the surgical morbidity and the recovery time for the patient are extremely reduced. The preliminary clinical and histological results are encouraging but the decree absolute on the efficiency of this method will be assessed at longer follow up.
This prospective study analyses the histological results of autologous chondrocyte transplantation in patients with articular cartilage defects of the knee joint. Chondrocytes from a non-weight bearing area of the knee were harvested and then cultured in vitro. Re-implantation involved injection of the chondrocytes into the defect, which was then sealed with a collagen membrane. One year post-op, patients were evaluated by clinical, arthroscopic and histological assessment. A biopsy of the transplanted region was examined by staining with Erlich’s H&
E and Safranin 0, polarised light microscopy and by analysis with S100 and immunohistochemistry. Hyaline cartilage content was further assessed by examination of Type IIa &
lIb collagen mRNA expression using in-situ hybridisation. The median age was 31 years. 63 knees were treated. Solitary lesions were treated in 61 knees with two defects being treated in three knees (66 defects in total). The defects were located on the medial femoral condyle in 39 cases, lateral femoral condyle in 14, trochlea in 2 and patella in 11. The defect size ranged from 1–7 cm2 (mean area 3cm2 ). 40 patients had at least one-year follow-up. Using the Brittberg Rating, 11 had excellent results, with 15 good, 10 fair and 4 poor. The mean Lysholm and Gillquist scores improved from 44 pre-op to 77 one-year post-op. Biopsy at one year conftrmed the presence of hyaline cartilage in 22 out of 32 cases (69%). In-situ hybridisation confirmed the presence of Collagen type II in the deep zones of the biopsy with a fibrocartilaginous appearance superficially.
Many methods have been described over the past 5 years for repair of articular cartilage defects. The best reported results have been from the use of autologous chondrocyte transplantation (ACT)(1) and mosaicplasty.(2) There have, however, been no prospective clinical trials of these two methods. In this trial 70 patients were prospectively randomized to receive either autologous chondrocyte transplantation (37) or mosaicplasty (33) in the knee. 37 patients were female and 33 male. The average age was 32 years (16 – 44). The indications for surgery were persistent pain and mechanical symptoms in the knee with an isolated defect of the articular cartilage. 38 (56%) were post-traumatic, 12 (16%) due to osteochondritis dissecans, 10 (14%) due to previous meniscectomy, and 10 (14%) due to chondromalacia patellae. The size of the defects ranged from 2cm2 to 12cm2 (mean 4.8cm2). There were 35 defects on the medial femoral condyle, 13 on the lateral femoral condyle, 17 on the patella and 5 on the trochlear. 31 patients were undergoing primary surgery and 39 secondary surgery. All were independently reviewed using the Visual Analogue Pain Score, the Cincinatti Pain Score and the Stanmore Score. Patients were arthroscoped at one year with MRI scan and biopsies where possible.
Autologous chondrocyte implant (ACI) is a very effective technique in the treatment of chondral lesions in order to restore normal hyaline cartilage. This technique, reported for the first time by Peterson in 1994, is advised for young or middle-aged. active patients with a single painful chondral injury (3/4 grade of Outerbridge scale), starting from more than 2 cm². New tissue engineering techniques with the use of biomaterial derived from hyaluronic acid (HYAFF matrix) provide ideal support for the culture and proliferation of chondrocytes, allowing at the same time arthroscopic implant. There are many advantages of arthroscopic techniques: easy implant and less pain post-operatively; however, the indications for arthroscopic technique are still restricted: single chondral inury, 2–6 cm² in size and localisation at the femoral condyles. At the Department of Orthopaedic Surgery of the University “ Federico II ” of Naples starting from January 1996 to the present, 29 patients were treated with ACI. Eight patients (six men and two women) had an arthroscopic implant. Median age was 18; in seven patients an OCD of the medial femoral condyle was present and just one patient had a post-traumatic injury of the medial femoral condyle. Hyalograft was used in all cases. All patients underwent CPM starting from the second post-operative day and full charge was allowed after 2 months. All patients were evaluated by clinical examination with IKDC score and functional score (Tegner) at 3, 6 and 12 months after surgery and with a MNR at 6 and 12 months after surgery and then every year. Good results were found subjectively in 88% of the patients, with a complete lack of pain in 70% cases. Using the IKDC score good results were found in 85% of the cases (average score 90). With the Tegner score we reported an improvement in the level of activity in 60% of the cases. The MNR images, performed with standard sequences, fat-suppressed and in the last cases with dGEMRIC, showed the presence of regeneration tissue inside the chondral defects, with a signal very similar to that of the cartilage tissue, sometimes slightly deeper. Our experience shows that ACI is an effective way of treating chondral lesions with excellent results. We think that progress in the field of biomaterials will extend the indications for arthroscopic techniques, also allowing implants in larger lesions and at other sites.
The purpose of this study is to demonstrate the validity of the autologous chondrocytes transplantation (A.C.T.) technique implemented over the last 6 years in the treatment of osteochondral lesions of the talus. Our case study included 22 patients (12 males and 10 females), with an average age of 27 years affected by osteochondral lesions of the talus surface. All lesions were >
1.5 cm2, monofocal, and post-traumatic in origin. The first 9 patients received ACT (Genzyme technique) and the remaining 13 patients received ACT with an arthroscopic technique. In 6 of the patients, the cartilage harvested from the detached osteochondral fragment was used for culturing, avoiding the first step arthroscopy in the knee. Before surgery, all patients were assessed clinically, radiographically, and using MRIs. For clinical evaluation patients were assessed using the American Foot &
Ankle Society 100 point score. Before surgery the mean score was 48.4 points. 11 patients underwent second-look arthroscopy at one year during which a biopsy was harvested for histologic analysis of the reconstructed cartilage. Of these, 9 patients (Genzyme technique) also had hardware removed. The mean follow-up of the 22 patients was 36 months. At follow-up, all patients but one were satisfied with their results. With regards to the clinical results evaluated using the American Foot and Ankle Society score, an average of 90.5 was obtained at 24 months, while at 36 months the average score (19 patients) was 94.0 (range 54–100). During follow-up arthroscopy, 4 patients had mild fibrosis and 1 patient required regularization of flap overgrowth causing pain. The clinical and histological results have confirmed the validity of the surgical technique utilized with no subjective nor objective complications. An improvement of the symptoms and of articular function has also been observed: laboratory data confirmed the histological appearance of the newly formed hyaline cartilage in all cases evaluated. Immunohistochemistry showed a positive staining for collagen type II located in the extracellular matrix and in the chondrocytes in the healthy and transplanted cartilage biopsies. All the specimens studied were also positive for proteoglycans expression as was the Alcian blue reaction, which highlighted the presence of these fundamental components of a cartilaginous matrix.
Autologous chondrocyte transplantation is a two-stage procedure for treating full-thickness chondral and osteochondral joint lesions. It has been used in more than 1200 patients in Sweden and 8000 outside of Sweden. No serious general complications have been seen, no deep infections, no deep thrombosis. Relevant serious complications are graft delaminations, especially in partial or total loss of attatchment. These can be a result of inadequate surgical technique, too aggressive rehabilitation or too early return to competitive highimpact sports. They often occur 6–12 months postop. Marginal delaminations can be handled by debridement and microfracture. Partial and total graft delaminations need retransplantation. This can be performed with good result. More common complications are periosteal delamination and hypertrophy of the periosteal flap causing catching, pain and swelling. If symptoms does not disappear with a change in rehabilitation an arthroscopic debridement is necessary. Arthrofibrosis with limited R.O.M. is treated with intensified physical therapy. If that fails arthroscopic debridement is needed. Other relevant complications like infection and thrombosis could usually be prevented.
We have developed a novel, two-layered, collagen matrix seeded with chondrocytes for repair of articular cartilage. It consists of a dense collagen layer which is in contact with bone and a porous matrix to support the seeded chondrocytes. The matrices were implanted in rabbit femoral trochleas for up to 24 weeks. The control groups received either a matrix without cells or no implant. The best histological repair was seen with cell-seeded implants. The permeability and glycosaminoglycan content of both implant groups were nearly normal, but were significantly less in tissue from empty defects. The type-II collagen content of the seeded implants was normal. For unseeded implants it was 74.3% of the normal and for empty defects only 20%. The current treatments for articular injury often result in a fibrous repair which deteriorates with time. This bilayer implant allowed sustained hyaline-like repair of articular defects during the entire six-month period of observation.
Since June 2002 15 hip autologous chondrocyte transplantations were arthroscopically performed for both acetabular roof and femoral head chondral defects. 15 Patients affected by chondral defect in the hip joint were treated with autologous chondrocyte transplantation. The mean follow up was 13.8 months (range 16 – 12 months) and the chondral defect was classified as 3rd – 4th degree, according to the Outerbridge’s classification. The defects were located on the acetabular roof in 12 cases, on the femoral head in 2 cases and on booths articular surfaces in 1 case. 9 patients were female and 6 male. The mean age was 40.7 years (from 52 to 22).In all cases the procedure was arthroscopically performed. A Bioseed C tissue was employed as a scaffold for chondrocytes, cultured in a tridimentional shape. A group of untreated 15 patients, matched for chondral defect degree, sex distribution and mean age was selected as control. All the Patients of both groups were pre and post operatively evaluated with the Harris Hip Score (HHS). Patients treated with hip autologous chondrocyte transplantation significantly improved after surgery (mean pre-op HHS 51.3; mean post-op HHS 85.3) compared with the untreated group (mean pre-op HHS 52.1; mean post-op HHS 64.5). Worst results were obtained in Patients affected by chondral defect located on the femoral head and when the joint space was reduced. Hip arthroscopy steel represent a new approach for treatment of hip’s disorders. Chondral defects of the hip can be treated with autologous chondrocyte transplantation, performed by hip arthroscopy. This study demonstrates the efficacy of this procedure compared with untreated patients.
These figures represent the early results of this study performed at this unit.
The aim of this study was to determine whether the clinical outcome of autologous chondrocyte transplantation was dependent on the timing of a high tibial osteotomy in tibio-femoral mal-aligned knees. Between 2000 and 2005, forty-eight patients underwent autologous chondrocyte implantation with HTO performed at varying times relative to the second stage autologous chondrocyte implantation procedure. 24 patients had HTO performed simultaneously with their second stage cartilage transplantation, (the HTO Simultaneous Group). 5 patients had HTO prior to their cartilage procedure, (the HTO pre-ACI Group) and 19 had HTO performed between 1 to 4 years after their second stage cartilage implantation, (the HTO post-ACI Group). There were 29 men and 19 women with a mean age of 37 years (Range 28 to 50) at the time of their second stage procedure. With average follow-up of 72 months we have demonstrated a significant functional benefit in performing the HTO either prior to or simultaneously with the ACI procedure in the mal-aligned knee. The failure rate in the Post-ACI group was 45% compared to the Pre-ACI and Simultaneous group, with failure rates of 20% and 25%, respectively. An HTO performed prior to or simultaneously with an autologous chondrocyte implantation procedure in the mal-aligned knee, provides a significant protective effect by reducing the failure rate by approximately 50%.
The research question was: can Arthroscopic or open biopsies were obtained, with informed consent and institution-approved review protocol, from patients undergoing total shoulder replacement or orthopaedic interventions for end-stage rotator cuff deficiency or arthropathy. Chondrocytes were isolated from eight biopsies and cells cultured over 4-weeks. In the first week post-digestion, validation studies showed cell counts varying from 30 000 to 400 000 (mean 126 666) and viability ranging from 30% to 100% (mean 75.2%). No primary culture failures were observed. One of the eight had an unexplained lower cell count and viability. Viability exceeded 80% in six of the eight cultures (75%). Alcian Blue stains and flow cytometry (Facscan) confirmed stable cultures with matrix formation. Aggrecan studies are in progress. The fact that